Abstract

BackgroundGanciclovir (Cymevene) has traditionally been the drug of choice for the treatment of cytomegalovirus infections; it should be administered intravenously because it has low bioavailability. The development of the highly...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call